Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

Moore, Kathleen N

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Apr 2017 - 1112-1118 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article

1527-7755

10.1200/JCO.2016.69.9538 doi


Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized--adverse effects
Antineoplastic Agents--adverse effects
Diarrhea--chemically induced
Disease-Free Survival
Drug Resistance, Neoplasm
Fallopian Tube Neoplasms--chemistry
Fatigue--chemically induced
Female
Folate Receptor 1--analysis
Humans
Hypotension--chemically induced
Immunoconjugates--adverse effects
Maytansine--adverse effects
Middle Aged
Nausea--chemically induced
Ovarian Neoplasms--chemistry
Peritoneal Neoplasms--chemistry
Platinum Compounds--therapeutic use
Response Evaluation Criteria in Solid Tumors
Retreatment
Vision Disorders--chemically induced